Artificial intelligence and machine learning approaches effectively enhance diagnostic accuracy and facilitate the identification of distinct HFpEF phenotypes beyond traditional classifications.
AI and machine learning offer promising tools to improve diagnosis, phenotyping, and risk prediction in HFpEF, though challenges in interpretability and clinical integration remain.
Background: Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome characterized by frequent underdiagnosis, diverse etiologies, and limited therapeutic options. Given its complexity, artificial intelligence (AI) and machine learning (ML) offer promising avenues to decode high-dimensional, multi-modal healthcare data. This review aims to synthesize the current landscape of AI/ML applications in HFpEF, evaluating their potential to address critical unmet clinical needs. Methods: We conducted a comprehensive review of the literature focusing on AI/ML paradigms in HFpEF. Key methodological frameworks were examined, including supervised, unsupervised, semi-supervised, and reinforcement learning, alongside advanced techniques such as deep learning and natural language processing (NLP). The analysis focused on the application of these techniques across four domains: diagnosis, sub-phenotyping, risk prediction, and optimization of diagnostic modalities, with specific emphasis on studies incorporating external validation. Results: Current evidence demonstrates that AI approaches effectively enhance diagnostic accuracy and facilitate the identification of distinct HFpEF phenotypes beyond traditional classifications. These technologies show significant utility in refining prognostic assessments and optimizing diagnostic testing strategies. Furthermore, ML-driven analytics provide a robust framework for improving patient selection and streamlining clinical trial design, potentially overcoming historical barriers to drug development in this population. Conclusions: AI represents a transformative tool capable of dissecting the heterogeneity of HFpEF to enable precision medicine. While the potential to improve clinical outcomes is substantial, challenges regarding model interpretability, bias, and clinical integration persist. Future efforts must focus on rigorous external validation and prospective trials to ensure the responsible translation of these technologies into routine clinical practice.
X et al. (Sat,) conducted a review in Heart failure with preserved ejection fraction (HFpEF). Artificial intelligence and machine learning was evaluated. Artificial intelligence and machine learning approaches effectively enhance diagnostic accuracy and facilitate the identification of distinct HFpEF phenotypes beyond traditional classifications.